Dr. Overman on Ongoing Research With Immunotherapy in Microsatellite Stable CRC
May 6th 2020Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).
Read More
Dr. Overman on Investigational Targeted Therapies in mCRC
March 11th 2020Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).
Read More
Dr. Overman on Tailoring Approaches to Molecular Subsets in mCRC
April 26th 2019Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses tailoring approaches to molecular subsets of patients with metastatic colorectal cancer.
Read More
Dr. Overman Discusses Progress With Immunotherapy in GI Cancer
January 12th 2019Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses progress made with immunotherapy agents in gastrointestinal (GI) cancer.
Read More
Dr. Overman on Next Steps With Immunotherapy in mCRC
December 20th 2018Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.
Read More
Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC
November 17th 2018Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).
Read More
Dr. Overman on the Impact of Nivolumab in mCRC
March 21st 2018Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).
Read More
Dr. Overman on Remaining Questions With Immunotherapy in CRC
February 20th 2018Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer.
Read More
Dr. Overman Discusses Immunotherapy and MSI Testing in CRC
February 8th 2018Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy and microsatellite instability (MSI) testing in colorectal caner (CRC).
Read More
Dr. Overman Discusses Nivolumab in Patients With dMMR/MSI-H mCRC
January 24th 2018Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses nivolumab (Opdivo) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic CRC.
Read More
Dr. Overman on Updated Findings With Nivolumab in Metastatic CRC
January 21st 2018Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer during the 2018 Gastrointestinal Cancers Symposium.
Read More
Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC
January 20th 2017Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
Read More
Dr. Overman on Implications of Tumor Location Data for Patients With mCRC
July 11th 2016Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.
Read More
Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC
June 15th 2016Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.
Read More